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Abstract
Background: Amplifications at 6p22.3 are prevalent in advanced stage bladder cancer (TCC).
Previous studies have identified SOX4,  CDKAL, and E2F3  as targets of this amplification and
therefore potential oncogenes, but the more telomeric DEK gene too has been reported as
overexpressed and amplified. We have therefore investigated whether the intermediate region
harboring the oncogene candidate ID4 is also part of the amplicon.
Results: Expression of E2F3, DEK, and ID4 was investigated by real-time RT-PCR in 28 TCC
compared to 6 normal bladder tissues and in 15 TCC cell lines compared to cultured normal
urothelial cells. Expression of E2F3 as well as DEK increased on average in tumor vs. normal tissues
(3-fold and 2.5-fold, resp.), but only the increase for E2F3 was statistically significant (p = 0.039).
ID4 overexpression was observed in selected specimens. Each of the three genes was
overexpressed in several cell lines, up to 150-fold (ID4), 30-fold (E2F3), and 9-fold (DEK), but these
increases were not correlated to each other. Instead, moderate (DEK) to excellent (ID4)
correlations were observed with copy number increases of microsatellites near each gene.
Microsatellite copy number increases were highly heterogeneous across the investigated several
Mb region revealing at least three subregions of amplification.
Conclusion: Extending previous reports, our data indicate that the 6p22.3 amplicon in TCC is
highly heterogeneous and targets several genes in a variable fashion. Among these, expression of
E2F3 and DEK appear to be generally increased in TCC, with additional increases caused by
amplifications. In contrast, over-expression of ID4, which is normally predominantly expressed in
testes and brain, appears to depend more strictly on gene amplification. Accordingly, the effect of
amplifications at 6p22.3 in bladder cancer is expected to be non-uniform, thereby contributing to
the highly variable biological and clinical behavior of advanced stage tumors. ID4 is a potential
oncogene in a small subset of bladder cancers.
Background
Urothelial carcinoma, which is commonly called bladder
cancer, occurs in two forms, a more prevalent papillary
subtype and a rarer, but much more invasive subtype
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[1,2]. Invasive bladder cancers usually develop from
highly dysplastic carcinoma in situ, but some papillary
tumors also progress to an invasive form. While papillary
cancers often contain a limited number of chromosomal
alterations, invasive cancers are characterized by a high
degree of chromosomal instability [3,4]. Even T1 stage
cancers, which have only invaded the lamina propria
underlying the urothelium, often exhibit multiple chro-
mosomal changes. Cancers at more advanced stages accu-
mulate further chromosomal alterations. In particular,
they harbor amplifications, e.g. of regions from chromo-
somes 5p, 6p, 8q, 11q, and 20q [4-7]. It is generally
assumed that chromosomal segments consistently ampli-
fied in a cancer contain oncogenes [8]. Accordingly, genes
amplified in advanced bladder cancers would be expected
to contribute to the progression of this cancer.
One of the most consistently amplified region in
advanced bladder cancers is located at 6p22.3 [5-7,9-12].
This amplification is detected in up to 25% of advanced
stage bladder cancers and is present in many bladder can-
cer cell lines. The cell lines harboring this amplification
provide a convenient experimental access to map the
amplified region precisely and identify potential urothe-
lial carcinoma oncogenes. Mapping of the 6p22.3 ampli-
con has been performed by several groups who have
identified different genes as potential targets of the ampli-
fication (Figure 1). In a first study [5], SOX4 was identified
as a frequent, but not entirely consistent amplification tar-
get. Further studies revealed that many amplifications also
included  E2F3  and the encoded protein was over-
expressed, particularly in high stage and high grade
urothelial cancers [6,11,12]. A high resolution analysis by
microarray-based comparative genomic hybridization
identified CDKAL1 located between SOX4 and E2F3 as the
most commonly amplified gene [7]. Another study indi-
cated that DEK located further telomerically (Figure 1)
may be amplified in a substantial proportion of bladder
cancer tissues [10]. DEK  was also found to be over-
expressed in a cDNA microarray study, albeit predomi-
nantly in early stage tumors [12].
This somewhat confusing state may owe partly to the fact
that many studies were performed prior to the publication
of the finished sequence of chromosome 6 in October
2003 [14] and partly to the use of different techniques.
Alternatively, the differences between the studies could
The chromosome 6p22.3 region Figure 1
The chromosome 6p22.3 region. Verified genes are drawn to size as grey boxes and the location of microsatellites used 
(the prefix D6S is omitted) is indicated.Molecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
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also mean that the region of amplification is not uniform
and that multiple genes might be targets.
Most previous studies have focussed on a more centro-
meric region within 6p22.3 containing SOX4, CDKAL1,
and E2F3 (Figure 1). DEK is located about 2 Mb more tel-
omeric of these genes. The interval framed by E2F3 and
DEK contains another plausible oncogene candidate, i.e.
ID4. The ID proteins ('inhibitor of differentiation') are
named for their ability to bind and inhibit cell-type spe-
cific helix-loop-helix transcriptional activators inducing
cell differentiation. Accordingly, they tend to stimulate
cell proliferation, and have been implicated in various
cancers [15-18]. Compared to ID1 and ID2, ID4 is a less
well characterized member of the family. It is expressed in
a tissue-specific manner, with the highest levels in testes
and brain [19]. In the present study, we have therefore
investigated to which extent ID4 gene copy numbers and
expression are affected by 6p22 amplifications in bladder
cancer, in comparison to E2F3 and DEK.
Results
Expression of 6p22 genes in bladder cancer cell lines
First, expression of ID4 mRNA in comparison to E2F3 and
DEK mRNAs was investigated by real-time PCR in 16 TCC
cell lines (Figure 2). Normal urothelial cells (UP) prolifer-
ating in culture and testicular tissue samples served as
controls. Expression at least twice as strong as in normal
urothelial cells was considered as over-expression.
According to this criterion, twelve cell lines over-expressed
ID4, with a maximum >150fold increase in HT1376. In 6
cell lines, E2F3  was over-expressed. The E2F3  over-
expressing cell lines included HT1376 and 5637 in line
with previous reports [7,11]. 5637 displayed a >30fold
increased level of E2F3 mRNA. Six cell lines over-
expressed  DEK, although the relative increases were in
general more moderate, with a maximum 9fold increase
in RT112. Inspecting Figure 2 may suggest that cell lines
over-expressing one gene also tended to over-express one
or both others. However, this tendency was not reflected
in a statistically significant correlation. Specifically,
expression did not significantly correlate for any pair of
genes, the best correlation coefficient reaching 0.39
between ID4 and DEK. The divergence is strikingly illus-
trated by the cell lines HT1376 and 5637, which presented
increased expression levels for all three genes, but with
either  ID4  or  E2F3  displaying particularly pronounced
increases (Figure 2).
Gene amplification analysis
To determine whether the increases in mRNA expression
were due to gene amplification, copy numbers were inves-
Expression of 6p22 genes in bladder cancer cell lines Figure 2
Expression of 6p22 genes in bladder cancer cell lines. Levels of mRNAs for ID4 (grey bars), E2F3 (black bars), and DEK 
(white bars) were determined by real-time RT-PCR relative to β -actin mRNA. As controls, shown to the left and right of the 
cancer cell lines, two independent primary cultures of normal urothelial cells (UP93 and UP94) and two different normal testic-
ular tissues were used. All values were determined by at least triplicate measurements, with further repeats, if deviations 
exceeded 20% of the mean. Arbitrary units are given; values for E2F3 and DEK were divided by 10.Molecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
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tigated for eight microsatellite loci located in 6p22.3. Five
were located around ID4, from D6S422 close to E2F3 to
DS1946, and three were located around DEK, including
the intragenic marker D6S2051 (Figure 1). The results
(Figure 3) demonstrate a considerable variation in the
microsatellite copy numbers across the region, even
within the same cell line. For instance, in HT1376 the
copy numbers of the eight microsatellites ranged from
approximately 0.5 to 13 normal genome equivalents,
which would correspond to 1 – 26 copies in a diploid cell.
As all bladder cancer cell lines are aneuploid, typically
hypo- or hypertriploid with a modal distribution,
between 2 – 40 copies would be present in a single cell. In
HT1376 specifically, two different segments of amplifica-
tion are discernible, one telomeric to DEK  and one
around ID4. In fact, amplification of the region including
E2F3 and of SOX4 has been shown previously in this line
[7,9,11]. Thus, there are at least three distinct regions of
amplification in this cell line. In contrast, no amplifica-
tion of microsatellites telomeric of D6S422 was evident in
5637, which contains increased copy numbers of E2F3
and SOX4 [7,9,11]. A more homogeneous increase of all
more telomeric markers including those close to ID4 and
DEK was seen in J82. RT112 contained a selective amplifi-
cation of the D6S2051 marker located in the DEK gene in
accord with the maximum expression of this gene in this
cell line. None of the microsatellites showed increased
copy numbers in T24 or SD, although E2F3 as well as
DEK, but not ID4 were overexpressed in T24.
Copy numbers of 6p22 microsatellites in bladder cancer cell lines Figure 3
Copy numbers of 6p22 microsatellites in bladder cancer cell lines. Microsatellite copy numbers (see Fig. 1 for their 
location) were determined as described in the methods section in the cell lines (A-F) HT1376, 5637, J82, RT112, SD, and T24. 
Normal genome equivalents determined from leukocyte DNA were set as 1.Molecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
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Expression of ID4  correlated excellently with the copy
numbers of each of the microsatellites around the gene,
yielding coefficients between 0.89 and 0.95 (Figure 4A). A
closer inspection shows however that this strong correla-
tion is primarily caused by the cell lines with clear-cut
amplifications of the region, i.e. J82 and HT1376 while at
lower copy numbers the relationship is essentially ran-
dom. DEK expression correlated moderately well with the
copy number of the intragenic D6S2051 marker (Figure
4B). E2F3 expression showed the best correlation with the
microsatellite marker D6S422 located most closely to the
gene (Figure 4C). However, this apparent correlation was
mostly due to the strongly increased copy number of
D6S422 in the 5637 cell line; if this data point is removed,
the relationship is essentially random.
6p22 gene expression in bladder cancer tissues
To determine whether the results from the cell lines can be
extended to bladder cancer tissues, the expression of the
three genes was determined in 28 tumor tissue samples
and 6 morphological normal samples from cystectomy
specimens by real-time RT-PCR (Figure 5, Table 1). In
accord with previous reports, expression of E2F3 mRNA
and DEK mRNA were often increased in tumor compared
to normal tissues. Median E2F3 mRNA expression was
2.24 arbitrary units in cancers compared to 0.72 in nor-
mal tissues, i.e. about threefold higher. This difference
Relationship of 6p22 gene expression changes to copy number changes of adjacent microsatellites in bladder cancer cell lines Figure 4
Relationship of 6p22 gene expression changes to copy number changes of adjacent microsatellites in bladder 
cancer cell lines. A: ID4 mRNA vs. D6S1128E (r = 0.95), B: DEK mRNA vs. D6S2051 (r = 0.57), C: E2F3 mRNA vs. D6S422 
(r = 0.79),Molecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
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was statistically significant (p = 0.039). Median DEK
mRNA expression was 1.26 compared to 0.52, i.e. 2.5fold
higher, but the difference did not reach statistical signifi-
cance. In contrast, ID4 expression essentially did not dif-
fer between normal and cancer tissues. Instead, individual
cancer specimens showed strongly increased expression
beyond the range of normal tissues.
Discussion
Taken together with previous analyses of 6p22.3 amplifi-
cations in bladder cancer, the present study has implica-
tions concerning the structure of 6p22.3 amplicons, the
effect of the amplification on gene expression, and more
generally, concepts of the significance of gene amplifica-
tion in human cancers. Specifically, the findings raise
interesting aspects with regard to ID4.
Our findings indicate that 6p22.3 amplifications in blad-
der cancer are even more heterogeneous than hitherto
assumed. Previous studies have identified the centromeric
region around CDKAL1 as part of an amplicon that often,
but not consistently included SOX4 and E2F3 [7,9,11,12].
The telomeric region around DEK had not been investi-
gated as well yet [10]. Our study confirms that this region
is also subject to copy number gains and amplifications.
Specifically, our findings are in good accord with ref. [10]
describing frequent copy numbers gains of microsatellites
around DEK, but at highly variable frequencies. The three
Expression of genes at 6p22.3 in bladder cancer tissues Figure 5
Expression of genes at 6p22.3 in bladder cancer tissues. Box plot representation of ID4 (left), E2F3 (center), and DEK 
(right) mRNA expression relative to β -actin mRNA as determined by real-time RT-PCR in 28 bladder cancer tissues (see Table 
1) and 6 morphologically normal bladder tissues. Note the different scales in the three figure parts.
ID4
0
1
2
3
4
NT
E2F3
0
2
4
6
8
10
12
14
NT
DEK
0
1
2
3
4
5
6
NTMolecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
Page 7 of 10
(page number not for citation purposes)
markers investigated in that study were located within 0.5
Mb and were amplified contiguously in 24% of the speci-
mens, whereas each of these three markers individually
was amplified in 45%, 56%, and 64% of the cases. Thus,
upon closer analysis, this region of amplification appears
also heterogeneous in itself. The intermediate region har-
boring ID4 had been more or less disregarded in previous
studies, but our data indicate that it is clearly gained or
even amplified in a certain number of cases, sometimes
concomitantly with, and sometimes independent of the
other two regions. In summary, therefore, one might dis-
cern three main segments of amplification, which split up
into further subregions in individual cancers. The 6p22.3
amplicon therefore seems to belong to a class which is
characterized by pronounced heterogeneity and great
structural complexity (see below).
Previous studies have variously identified SOX4,  E2F3,
CDKAL1, and DEK  as potential targets of the 6p22.3
amplification; the present study adds ID4 to this list. In
this regard, it is interesting to compare the cell line data,
where ID4 emerged as the most frequently over-expressed
gene with the tissue data which showed generalized
increases in expression of E2F3 and of DEK (Figure 1 vs.
Figure 5). This apparent discrepancy can be relatively sim-
ply resolved by two plausible assumptions. Normal blad-
der tissue is largely quiescent, albeit proliferation
increases strongly in response to tissue damage [20]. Thus,
urothelial cancers are distinguished from normal tissue
not only by expression of cancer-specific genes, but also
by generalized over-expression of genes associated with
cell proliferation. The generally increased expression of
E2F3 and DEK in the cancer tissues may reflect the latter
effect, with further increases in individual cases due to
deregulation and copy number gains of these genes. In
contrast, early passage cultured urothelial cells proliferate
as rapidly as cancer cell lines [21-23]. Therefore, the
increases in E2F3 and DEK in cultured cancer vs. normal
cells may turn out as comparatively moderate. In contrast,
ID4 expression has probably to be considered as ectopic
in bladder cancer, since it is normally restricted to other
tissues including testes and brain [19]. Thus, overexpres-
sion may more strictly depend on amplification of the
gene, particularly in tumor tissues.
Table 1: Tumor tissues investigated
Patient Tumor mRNA expression (AU)
No Sex Age Stage Lymph node status Metastasis status Grade E2F3 ID4 DEK
3 m 75 pT3b N0 M0 G2 5.59 0.48 4.88
6 m 76 pT3b pN2 M0 G3 10.37 0.36 1.37
12 m 70 pT3a N0 M0 G3 1.73 0.04 1.99
28 m 72 pT3b N0 M0 G3 3.73 0.24 2.27
41 f 54 pTa Nx Mx G2 11.69 0.49 3.29
47 m 76 pT3b N0 M0 G3 3.75 0.19 1.84
52 f 87 pT3b N0 M0 G3 2.86 0.25 1.43
55 m 83 pT4a N1 M0 G3 1.25 0.18 0.52
61 m 75 pT3b N0 M0 G3 1.98 0.12 1.48
62 f 78 pT3b N0 M0 G2 1.60 0.54 0.72
64 m 74 pT3b N2 M0 G3 3.34 0.11 1.26
67 f 94 >pT2 Nx Mx G3 4.38 0.33 1.50
69 m 77 pT3b N0 M0 G3 2.17 0.14 1.19
104 m 61 pT1 N0 M0 G2 1.49 0.24 0.72
105 m 83 pTa Nx M0 G2 3.80 0.27 1.88
109 m 68 pT4a N0 M0 G3 2.14 0.23 0.30
111 m 81 pT3b N0 M0 G2-3 2.24 0.52 0.61
115 m 74 pT3a N2 M0 G3 1.74 0.12 0.84
120 m 66 pT2 N0 Mx G2 3.12 0.15 0.66
150 f 78 pT3a N2 M0 G3 0.54 0.20 0.86
168 m 64 pT3a N2 M0 G3 1.68 0.12 1.42
170 f 63 pT2 N0 M0 G2 0.58 0.08 0.27
172 m 72 pT3a N0 M0 G3 1.73 0.13 0.85
205 f 65 pT2 N0 M0 G2 0.36 0.10 0.17
212 m 73 pT2a N1 M0 G2 0.62 0.16 0.79
224 m 65 pT2a N0 M0 G2 4.29 3.39 1.87
231 m 95 >pT2 Nx M0 G2 13.04 1.11 1.59
246 m 67 pT4a N2 M0 G3 3.07 0.27 1.29Molecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
Page 8 of 10
(page number not for citation purposes)
It is commonly assumed that regions in the genome that
are amplified in cancers harbor proto-oncogenes that are
activated by overexpression as a consequence of increased
gene dosage. Indeed, several bona fide oncogenes have
been found in amplified regions and some have even
been identified by cloning from amplicons. In such cases,
amplicons consistently contain one particular gene, alone
or together with a limited number of others, e.g. ERBB2
only or together with TOP2A. Interestingly, the structure
of such amplicons can be quite simple [24-26]. The mech-
anism underlying such amplifications is not understood
in detail, but appears to involve the re-replication of a sin-
gle chromosome fragment, most likely via a circular dou-
ble-minute intermediate [26].
Clearly, the 6p22 amplicon in bladder cancer belongs to a
different class of amplicons which are characterized by
great heterogeneity and instability. Such amplicons often
contain different segments and accordingly different
genes from one region and even sequences from different
chromosomes [27-30]. The mechanism causing these
amplifications is considered to be most likely breakage-
fusion-bridge cycles initiated e.g. by hypoxia [31] or
breakage at fragile sites [32].
Considering this background, the question which is the
oncogene targeted by 6p22 amplifications in bladder can-
cer and the specific issue of the role of ID4 have to be
approached with due caution, since in each individual
case the amplicon may be influenced by random factors
such as the location of an initiating double-strand break
and structural factors such as preferred sites of breakage of
dicentric chromosomes arising during breakage-fusion-
bridge cycles. Nevertheless, the relatively high prevalence
of 6p22 amplifications in bladder cancer and the relative
specificity of this amplification for this cancer type argue
for a functional selection as well.
For several 6p22 genes subject to amplification, it is plau-
sible to assume that their overexpression may confer a
more aggressive phenotype to bladder cancer cells. SOX
factors determine cell fate and cell differentiation [33], so
SOX4 overexpression might lead to further dedifferentia-
tion. E2F transcription factors activate the transcription of
genes required for DNA synthesis and E2F3 appears to
repress some promoters that are activated by E2F1, includ-
ing the ARF promoter in CDKN2A [34]. DEK is part of a
oncogenic fusion protein resulting from t(6;9)(p23;q34)
translocations in acute myeloid leukemia [35] and is
implicated in regulation of chromatin structure, which is
evidently aberrant in invasive bladder cancers. However,
specific functional studies on the role of these proteins in
urothelial cells are lacking. The function of CDKAL1 is
entirely unknown.
ID4 belongs to a protein family whose members have
been shown to interfere with cell differentiation by block-
ing the effects of HLH transcription factors and pocket
proteins, including RB1. Several members have been
reported to be over-expressed in human cancers [15-18].
ID4 in particular has been shown to be overexpressed in
rat mammary carcinomas. Accordingly, overexpression of
ID4 blocked the differentiation of HC11 mammary epi-
thelial cells and stimulated their proliferation [36]. It is
also the target of a specific chromosomal translocation in
some cases of B-cell acute lymphoblastic leukemia [37].
Conversely, ID4 expression has been reported to be
down-regulated by promoter hypermethylation in colon
carcinomas [38]. Evidently, as for the other oncogene can-
didates on 6p22, more detailed studies are required on the
biochemical and functional properties of ID4 in normal
and cancerous urothelial tissue.
Conclusion
In conclusion, our study indicates that the 6p22.3 ampli-
fication prevalent in advanced bladder cancers is highly
heterogeneous and contributes to the altered expression
of several genes, including ID4, in a highly variable man-
ner. Thus, this genetic change may contribute to the
highly variable biological and clinical behaviour of inva-
sive bladder cancers.
Methods
Tissues
Cancerous and normal bladder tissues were used from a
previous study [39]. Normal tissues were identified by
gross morphology, with microscopic verification in case
of extended tumors. Important clinical parameters of the
cancer tissues are summarized in Table 1. RNA from tes-
ticular normal and cancer tissues used as a control for ID4
expression was also prepared in the course of a former
study [40].
Cell lines and primary cultures
The bladder cancer cell lines 253J, 639v, 5637, BFTC905,
BFTC909, EJ, HT1376, J82, MGHU4, RT112, SD,
SW1710, T24, UMUC3, VMCub1, and VMCub2 and pri-
mary urothelial cells were cultured as described previously
[23].
DNA and RNA extraction
High-quality DNA and RNA were extracted by standard
methods using commercial kits from Qiagen (Hilden,
Germany) and Peqlab (Erlangen, Germany).
RT-PCR
Following photometric quantification, 2 µg mRNA were
transcribed into first strand cDNA using SuperscriptII
(Invitrogen, Karlsruhe, Germany) according to the manu-
facturer's protocol with oligo-dT primers. Real-time RT-Molecular Cancer 2005, 4:16 http://www.molecular-cancer.com/content/4/1/16
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PCR was carried out using a LightCycler instrument
(Roche Diagnostics, Mannheim, Germany) and the prim-
ers indicated in Table 2. The amplification mixture con-
sisted of 1x reaction mix (LightCycler-FastStart DNA
Master PLUS SYBR Green I; Roche Diagnostics), 10
pmoles (DEK, E2F3, ID4) or 5 pmoles (β -actin) of each
primer and 20 ng cDNA in a final volume of 10 µl. The
reaction was monitored between the annealing and elon-
gation steps at 640 nm. After the final cycle, melting-point
analysis of the samples was performed over the range of
69°C – 99°C. Turning-point values for the specific genes
were related to those for β -actin.
Microsatellite analysis
Microsatellites located at 6p22 (see Figure 1) were ampli-
fied using published primer sets (see the ensembl data-
base for sequences and Tms) in duplex reactions with one
microsatellite from chromosome 12 (D12S1650) or chro-
mosome 15 (D15S127) as control. These chromosome
are rarely affected by allelic imbalances in bladder cancer
[3]. One primer from each pair was labeled with IRD-800
fluorescence and the products were resolved and detected
on a LiCOR 4200S automated sequencer. Reactions were
carried out in the linear phase of PCR with 25–30 cycles,
the precise number being determined for each primer
pair. Band intensities were quantitatively determined by
ONE-D-SCAN (MWG-Biotech, Ebersberg, Germany).
Leukocyte DNA standards were included in each set of
reaction. The ratio of intensities of chromosome 6 and
chromosome 15 microsatellites in these was set as 1 for
each pair.
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